173 related articles for article (PubMed ID: 29154771)
1. In-vitro blockade of the CD4 receptor co-signal in antigen-specific T-cell stimulation cultures induces the outgrowth of potent CD4 independent T-cell effectors.
Vatter S; Schmid M; Gebhard C; Mirbeth C; Klobuch S; Rehli M; Herr W; Thomas S
J Immunol Methods; 2018 Mar; 454():80-85. PubMed ID: 29154771
[TBL] [Abstract][Full Text] [Related]
2. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
[TBL] [Abstract][Full Text] [Related]
3. Avidity characterization of genetically engineered T-cells with novel and established approaches.
Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus-transformed B-cells as efficient antigen presenting cells to propagate Aspergillus-specific cytotoxic T-lymphocytes.
Ramadan G
Egypt J Immunol; 2008; 15(1):145-57. PubMed ID: 20306679
[TBL] [Abstract][Full Text] [Related]
5. In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara.
La Rosa C; Wang Z; Lacey SF; Lalimarmo MM; Krishnan A; Longmate J; Diamond DJ
Exp Hematol; 2006 Apr; 34(4):497-507. PubMed ID: 16569596
[TBL] [Abstract][Full Text] [Related]
6. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
7. Transfer of in vitro-expanded naïve T cells after lymphodepletion enhances antitumor immunity through the induction of polyclonal antitumor effector T cells.
Tanaka T; Watanabe S; Takahashi M; Sato K; Saida Y; Baba J; Arita M; Sato M; Ohtsubo A; Shoji S; Nozaki K; Ichikawa K; Kondo R; Aoki N; Ohshima Y; Sakagami T; Abe T; Moro H; Koya T; Tanaka J; Kagamu H; Yoshizawa H; Kikuchi T
PLoS One; 2017; 12(8):e0183976. PubMed ID: 28854279
[TBL] [Abstract][Full Text] [Related]
8. Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles.
Rosalia RA; Silva AL; Camps M; Allam A; Jiskoot W; van der Burg SH; Ossendorp F; Oostendorp J
Cancer Immunol Immunother; 2013 Jul; 62(7):1161-73. PubMed ID: 23613147
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of the antigen-specific cytotoxic T lymphocyte-inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector-mediated transduction of the caTLR4 gene.
Iwabuchi M; Narita M; Uchiyama T; Iwaya S; Oiwa E; Nishizawa Y; Hashimoto S; Bonehill A; Kasahara N; Takizawa J; Takahashi M
Mol Med Rep; 2015 Aug; 12(2):2443-50. PubMed ID: 25936433
[TBL] [Abstract][Full Text] [Related]
11. Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens.
Van Nuffel AM; Tuyaerts S; Benteyn D; Wilgenhof S; Corthals J; Heirman C; Neyns B; Thielemans K; Bonehill A
J Immunol Methods; 2012 Mar; 377(1-2):23-36. PubMed ID: 22269772
[TBL] [Abstract][Full Text] [Related]
12. Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells.
Koido S; Tanaka Y; Tajiri H; Gong J
Vaccine; 2007 Mar; 25(14):2610-9. PubMed ID: 17239504
[TBL] [Abstract][Full Text] [Related]
13. CD11c(+) dendritic cells maintain antigen processing, presentation capabilities, and CD4(+) T-cell priming efficacy under hypercholesterolemic conditions associated with atherosclerosis.
Packard RR; Maganto-García E; Gotsman I; Tabas I; Libby P; Lichtman AH
Circ Res; 2008 Oct; 103(9):965-73. PubMed ID: 18832748
[TBL] [Abstract][Full Text] [Related]
14. Co-receptor-independent signal transduction in a mismatched CD8+ major histocompatibility complex class II-specific allogeneic cytotoxic T lymphocyte.
Eshima K; Tachibana M; Suzuki H; Yamazaki S; Shinohara N
Eur J Immunol; 1997 Jan; 27(1):55-61. PubMed ID: 9021998
[TBL] [Abstract][Full Text] [Related]
15. Human leucocyte antigen class I-redirected anti-tumour CD4
Tan MP; Dolton GM; Gerry AB; Brewer JE; Bennett AD; Pumphrey NJ; Jakobsen BK; Sewell AK
Clin Exp Immunol; 2017 Jan; 187(1):124-137. PubMed ID: 27324616
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
[TBL] [Abstract][Full Text] [Related]
17. IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4(+) T cells.
Ohno Y; Kitamura H; Takahashi N; Ohtake J; Kaneumi S; Sumida K; Homma S; Kawamura H; Minagawa N; Shibasaki S; Taketomi A
Cancer Immunol Immunother; 2016 Feb; 65(2):193-204. PubMed ID: 26759006
[TBL] [Abstract][Full Text] [Related]
18. Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy.
Yao X; Lu YC; Parker LL; Li YF; El-Gamil M; Black MA; Xu H; Feldman SA; van der Bruggen P; Rosenberg SA; Robbins PF
J Immunother; 2016 Jun; 39(5):191-201. PubMed ID: 27163739
[TBL] [Abstract][Full Text] [Related]
19. Extracellular domains of CD8α and CD8ß subunits are sufficient for HLA class I restricted helper functions of TCR-engineered CD4(+) T cells.
van Loenen MM; Hagedoorn RS; de Boer R; Falkenburg JH; Heemskerk MH
PLoS One; 2013; 8(5):e65212. PubMed ID: 23738014
[TBL] [Abstract][Full Text] [Related]
20. Differential kinetics of antigen dependency of CD4+ and CD8+ T cells.
Rabenstein H; Behrendt AC; Ellwart JW; Naumann R; Horsch M; Beckers J; Obst R
J Immunol; 2014 Apr; 192(8):3507-17. PubMed ID: 24639353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
